Announced Date: 2025-07-28 (JULY 28, 2025)
Asset Name: HRS-9821 and other 11 preclinical medicines
Licensor: Hengrui Pharma (600276.SH; 01276.HK) (Headquarter Shanghai City, China)
Licensee (Buyer): GSK plc
.
Asset Target: PDE3/4 inhibitor(HRS-9821), etc
Asset Modality: Small Molecule, or other
Current Stage:HRS-9821 in Phase I, other 11 asset all in preclinical ;
.
Scope of Authority:
GSK will exclusive worldwide license (excluding mainland China, Hong Kong, Macau and Taiwan) for PDE3/4 inhibitor (HRS-9821) ;
GSK will have the exclusive option to further develop and commercialise each programme (up to 11 programmes) worldwide (excluding mainland China, Hong Kong, Macau and Taiwan), at the end of phase I or earlier at GSK’s election, as well as certain programme substitution rights.
.
Deal Detail:
Upfront payment of $500 million
Milestone payments up to approximately $12 billion
Royalties on net sales, tiered
Total 12.5 billion plus
.
Link:
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements/
